Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on February 10, 2021. The report details a material definitive agreement entered into on the same date with Juvenescence Limited regarding the company's loan facility.
Key Financial Metrics and Debt
- Loan Facility Increase: The total loan facility was increased from $2 million to $6 million.
- Outstanding Borrowings: As of the filing date, AgeX had previously borrowed $2 million under the original agreement.
- Additional Borrowing Capacity: Up to $4 million remains available, subject to Juvenescence's discretion, in $1 million denominations.
- Maturity Date: Extended to February 14, 2022.
- Origination Fee: A fee of $160,000 is payable upon repayment or conversion of the loan.
Material Changes Versus Prior Period
The primary material change is the amendment of the Loan Facility Agreement dated August 13, 2019. Key modifications include:
- Extension of the loan maturity date by approximately one year.
- Tripling of the total available credit facility.
- Introduction of conversion rights allowing Juvenescence to convert outstanding principal into AgeX common stock at the Market Price.
- Implementation of ownership caps: Conversion cannot exceed 19.9% of shares outstanding as of August 13, 2019, and cannot result in Juvenescence owning 50% or more of outstanding shares.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the potential conversion of debt and future funding, which are subject to risks detailed in AgeX's periodic reports. The company disclaims any obligation to update these statements. The amendment includes an amendment to the Registration Rights Agreement, ensuring that shares issued upon conversion of the loans or related warrants will be registered for resale under the Securities Act of 1933.
Important Facts for Investor Verification
- Verify the exact terms of the "Market Price" definition used for debt conversion in the full text of Exhibit 10.1.
- Confirm the current number of outstanding shares to assess the dilution impact of the 19.9% conversion cap.
- Review the discretion criteria Juvenescence will use to approve additional loan advances beyond the initial $2 million.
- Check the status of the March 30, 2020 Secured Convertible Facility Agreement mentioned in the Registration Rights Amendment.